Toward the Discovery of Novel Anti-HIV Drugs. Second-Generation Inhibitors of the Cellular ATPase DDX3 with Improved Anti-HIV Activity: Synthesis, Structure-Activity Relationship Analysis, Cytotoxicity Studies, and Target Validation
first nonnucleoside inhibitor of the ATPaseactivity of human DEAD‐box RNA helicase DDX3 led to the design and synthesis of second‐generation rhodanine derivatives with better inhibitory activitytowardcellularDDX3 and HIV‐1 replication. Additional DDX3inhibitors were identified among triazine compounds. Biological data were rationalized in terms of structure–activityrelationships and docking simulations